行情

JAZZ

JAZZ

爵士制药
NASDAQ

实时行情|Nasdaq Last Sale

146.74
+0.74
+0.51%
盘后: 146.74 0 0.00% 16:30 01/29 EST
开盘
146.42
昨收
146.00
最高
148.02
最低
146.04
成交量
44.65万
成交额
--
52周最高
154.24
52周最低
116.52
市值
83.01亿
市盈率(TTM)
14.04
分时
5日
1月
3月
1年
5年

分析师评级

18位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

JAZZ 新闻

  • Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)
  • Zacks.1天前
  • Why Jazz (JAZZ) Could Beat Earnings Estimates Again
  • Zacks.2天前
  • Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
  • Zacks.6天前
  • Jazz Pharma submits marketing application for JZP-258
  • seekingalpha.01/22 18:24

更多

所属板块

制药
+0.20%
制药与医学研究
+0.09%

热门股票

名称
价格
涨跌幅

JAZZ 简况

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
展开

Webull提供Jazz Pharmaceuticals PLC的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。